REPORT: TPG Capital shops drug maker Aptalis, finds no takers
This article was originally published in Scrip
Executive Summary
Private equity firm TPG Capital is shopping its specialty drug company Aptalis Pharma, asking for more than $3 billion, but the price is too rich for some potential buyers, according to Reuters.